FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Open Access
- 16 September 2021
- journal article
- review article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (3), e161-e184
- https://doi.org/10.1016/j.clml.2021.09.002
Abstract
No abstract availableThis publication has 66 references indexed in Scilit:
- Polypharmacy and the management of the older cancer patientAnnals of Oncology, 2013
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 2013
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationBlood, 2013
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe New England Journal of Medicine, 2013
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemiasHaematologica, 2010
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasLeukemia, 2010
- Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced CancersJournal of Clinical Oncology, 2009
- Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinomaEuropean Journal of Surgical Oncology, 2009
- DNA sequencing of a cytogenetically normal acute myeloid leukaemia genomeNature, 2008
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Blood, 2005